Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19

Nat Rev Clin Oncol. 2021 Jan;18(1):7-8. doi: 10.1038/s41571-020-00448-y.

Abstract

Randomized controlled trials designed to test cancer therapies often fail to clarify effectiveness in real-world settings. Herein, we explore lessons for trial development in oncology that can be learnt from the large-cohort, pragmatic RECOVERY trial involving patients hospitalized with COVID-19.

Publication types

  • Comment

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • COVID-19* / drug therapy
  • Dexamethasone* / therapeutic use
  • Humans
  • Inpatients
  • Oncologists
  • SARS-CoV-2

Substances

  • Anti-Inflammatory Agents
  • Dexamethasone

Supplementary concepts

  • COVID-19 drug treatment